Emmaus Life Sciences, Inc. 8-K

What Happened Emmaus Life Sciences, Inc. filed a Form 8-K reporting results of operations and financial condition. The company issued a press release on March 30, 2026 that discloses its financial results for the year ended December 31, 2025; that press release is included as Exhibit 99.1 and is incorporated by reference into the 8-K.

Key Details

• Filing date: March 30, 2026 (Form 8-K, Item 2.02).
• Reporting period: results of operations and financial condition for the year ended December 31, 2025.
• The press release containing the results is attached to the 8-K as Exhibit 99.1.
• The filing also lists exhibit information under Item 9.01 (Financial Statements and Exhibits).

Why It Matters This 8-K provides the company’s most recent annual operating and financial snapshot for 2025. Investors should read the attached press release (Exhibit 99.1) to see revenue, profit/loss, cash position and any management commentary, since those details can affect valuation and near-term market expectations. For a full financial picture, compare the press release numbers to the company’s periodic SEC filings and disclosures.